GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palatin Technologies Inc (LTS:0KF3) » Definitions » EV-to-EBIT

Palatin Technologies (LTS:0KF3) EV-to-EBIT : -0.56 (As of Jun. 01, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Palatin Technologies EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Palatin Technologies's Enterprise Value is $19.74 Mil. Palatin Technologies's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-35.48 Mil. Therefore, Palatin Technologies's EV-to-EBIT for today is -0.56.

The historical rank and industry rank for Palatin Technologies's EV-to-EBIT or its related term are showing as below:

LTS:0KF3' s EV-to-EBIT Range Over the Past 10 Years
Min: -74.61   Med: -1.39   Max: 123.82
Current: -0.56

During the past 13 years, the highest EV-to-EBIT of Palatin Technologies was 123.82. The lowest was -74.61. And the median was -1.39.

LTS:0KF3's EV-to-EBIT is ranked worse than
100% of 423 companies
in the Biotechnology industry
Industry Median: 10.04 vs LTS:0KF3: -0.56

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Palatin Technologies's Enterprise Value for the quarter that ended in Mar. 2024 was $19.93 Mil. Palatin Technologies's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-35.48 Mil. Palatin Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -177.99%.


Palatin Technologies EV-to-EBIT Historical Data

The historical data trend for Palatin Technologies's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Palatin Technologies EV-to-EBIT Chart

Palatin Technologies Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.08 -1.60 -2.43 -1.00 -0.45

Palatin Technologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.37 -0.45 -0.45 -1.35 -0.59

Competitive Comparison of Palatin Technologies's EV-to-EBIT

For the Biotechnology subindustry, Palatin Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Palatin Technologies's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Palatin Technologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Palatin Technologies's EV-to-EBIT falls into.



Palatin Technologies EV-to-EBIT Calculation

Palatin Technologies's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=19.739/-35.477
=-0.56

Palatin Technologies's current Enterprise Value is $19.74 Mil.
Palatin Technologies's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Palatin Technologies  (LTS:0KF3) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Palatin Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-35.477/19.9315192
=-177.99 %

Palatin Technologies's Enterprise Value for the quarter that ended in Mar. 2024 was $19.93 Mil.
Palatin Technologies's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Palatin Technologies EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Palatin Technologies's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Palatin Technologies (LTS:0KF3) Business Description

Traded in Other Exchanges
Address
4B Cedar Brook Drive, Cranbury, NJ, USA, 08512
Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction.

Palatin Technologies (LTS:0KF3) Headlines

No Headlines